Search research articles
Contact Us
Filters
Showing results (921-930 of 1,171) with videos related to
Page
of 118
Sort By:
British Journal of Cancer
|
December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
Geoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
Cancer
|
April 12, 2023
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors
Meghan J Mooradian, James M Cleary, Anita Giobbie-Hurder, et al.
American Journal of Physiology. Renal Physiology
|
March 6, 2009
Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy
Jihad Elkareh, Sankaridrug M Periyasamy, Amjad Shidyak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2016
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
Suzanne Leijen, Robin M J M van Geel, Anna C Pavlick, et al.
Annals of the American Thoracic Society
|
May 2, 2025
Endothelial Glycocalyx Degradation in Sepsis: Analysis of the Crystalloid Liberal Or Vasopressors Early Resuscitation in Sepsis (CLOVERS) Trial, a Multicenter, Phase 3, Randomized Trial
Kaori Oshima, Chiara Di Gravio, Bailu Yan, et al.
The New England Journal of Medicine
|
February 25, 2026
Phase 1 Study of Rezatapopt, a p53 Reactivator, in <i>TP53</i> Y220C-Mutated Tumors
Ecaterina E Dumbrava, Geoffrey I Shapiro, Aparna R Parikh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2010
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors
Jennifer R Diamond, Bruno R Bastos, Ryan J Hansen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 22, 2013
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2
Beata Holkova, Jeffrey G Supko, Matthew M Ames, et al.
Investigational New Drugs
|
November 26, 2013
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
Sharad Ghamande, Chia-Chi Lin, Daniel C Cho, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
February 15, 2011
Relationship between B-type natriuretic peptide and adverse outcome in patients with clinical evidence of sepsis presenting to the emergency department
Sarah M Perman, Anna Marie Chang, Judd E Hollander, et al.
Page
of 118
Search research articles
Search
Showing results (921-930 of 1,171) with videos related to
Sort By:
Page
of 118
British Journal of Cancer
|
December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
Geoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
Cancer
|
April 12, 2023
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors
Meghan J Mooradian, James M Cleary, Anita Giobbie-Hurder, et al.
American Journal of Physiology. Renal Physiology
|
March 6, 2009
Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy
Jihad Elkareh, Sankaridrug M Periyasamy, Amjad Shidyak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2016
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
Suzanne Leijen, Robin M J M van Geel, Anna C Pavlick, et al.
Annals of the American Thoracic Society
|
May 2, 2025
Endothelial Glycocalyx Degradation in Sepsis: Analysis of the Crystalloid Liberal Or Vasopressors Early Resuscitation in Sepsis (CLOVERS) Trial, a Multicenter, Phase 3, Randomized Trial
Kaori Oshima, Chiara Di Gravio, Bailu Yan, et al.
The New England Journal of Medicine
|
February 25, 2026
Phase 1 Study of Rezatapopt, a p53 Reactivator, in <i>TP53</i> Y220C-Mutated Tumors
Ecaterina E Dumbrava, Geoffrey I Shapiro, Aparna R Parikh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2010
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors
Jennifer R Diamond, Bruno R Bastos, Ryan J Hansen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 22, 2013
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2
Beata Holkova, Jeffrey G Supko, Matthew M Ames, et al.
Investigational New Drugs
|
November 26, 2013
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
Sharad Ghamande, Chia-Chi Lin, Daniel C Cho, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
February 15, 2011
Relationship between B-type natriuretic peptide and adverse outcome in patients with clinical evidence of sepsis presenting to the emergency department
Sarah M Perman, Anna Marie Chang, Judd E Hollander, et al.
Page
of 118